Synergy Innovation Signs Additional Agreement to Extend Payment Deadline for DSK Stock Purchase - No Change in Stake at 43.08%
The filer Synergy Innovation and its special relations entered into an additional contract on June 29, 2026, extending the payment deadline for the stock purchase agreement of 11,075,440 shares of DSK from June 29 to July 28, 2026. The stake remains unchanged at 43.08%.
This transaction involves a secondary sale of all shares held by the filer and its affiliates, resulting in no capital change or dilution for DSK's existing shareholders.
The closing is subject to conditions including regulatory approval for Botulinum toxin product and an extraordinary general meeting of DSK.
[AI Summary]Synergy Innovation extended the payment deadline for its DSK stake sale without altering its current holdings, indicating a delay in the change of control. No immediate dilution or capital impact, but the eventual transfer of a 43% stake poses governance transition risk.